- Poster presentation
- Open access
- Published:
HIV-infected patients in the ICU in the current era of high-activity antiretroviral treatment
Critical Care volume 15, Article number: P512 (2011)
Introduction
Our purpose is to study the effect of high-activity antiretroviral treatment (HAART) on the epidemiology and outcome of human inmunodefficiency virus (HIV) patients in the ICU. HAART has modified the outcome of patients infected with HIV, increasing survival and reducing infectious complications. In the first years of HAART use a significant change in the diagnosis and prognosis of ICU-admitted HIV patients has been identified, but there are no studies investigating this issue in the most recent years.
Methods
A retrospective study. HIV patients admitted to a 36-bed ICU, between January 2005 and December 2009 (HIV incidence in our population: 42 cases/million hab/year). We studied demographic characteristics, having or not HAART, final diagnosis, need for organ support and outcome (length of stay (LOS) and mortality).
Results
One hundred and five HIV-infected patients (70.5% being male), 52 (49.5%) having HAART. Mean age: 41 ± 8.57 years. More common co-morbidities were: hepatic disease (61%), cirrhosis in a 10.5%, followed by chronic respiratory disease and dyslipemia (12.4%), cardiac disease (5.7%), solid and hematologic malignancy (5.7% and 2.9%, respectively). A total 70.5% had a history of intravenous drugs use, and 13.3% were heavy alcohol consumers. Average CD4 count was 275.4 ± 362/ml, mean viral load was 3,656 ± 3,000/ml. A total 52.1% were on their CD4 nadir at admission time. Most frequent final diagnosis (grouped): infectious disease, 58.3% (focus: lung 66.7%, CNS 16.7%), cardiac disease (12.7%), intoxication and trauma (5.8% each one). Average APACHE II: 20.9. A total 48.6% of patients needed support with vasopressors, 64.7% mechanical ventilation and 15.2% renal support. A total 69.5% of patients needed at least one organ support. ICU LOS: 8.7 ± 9.9 days, hospital LOS: 29 ± 29.5. ICU mortality: 28.6%, hospital mortality: 35.2%.
Conclusions
Despite the beneficial effects of HAART on inmune status, infection (especially pneumonia) remains the most common cause of ICU admission. Our results confirm the trend to a lower mortality saw in early HAART period studies.
References
Powell , et al.: Survival for patients with HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest 2009, 135: 11-17. 10.1378/chest.08-0980
Croda , et al.: Benefit of antirretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med 2009, 37: 1605-1611. 10.1097/CCM.0b013e31819da8c7
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Cortés, P.V., Fernández, V.A., Fariña, M.M. et al. HIV-infected patients in the ICU in the current era of high-activity antiretroviral treatment. Crit Care 15 (Suppl 1), P512 (2011). https://doi.org/10.1186/cc9932
Published:
DOI: https://doi.org/10.1186/cc9932